Monopar Therapeutics Inc. (MNPR)

Market Cap	10.68M
Revenue (ttm)	n/a
Net Income (ttm)	-7.61M
Shares Out	17.48M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,996
Open	0.610
Previous Close	0.612
Day's Range	0.600 - 0.629
52-Week Range	0.274 - 1.750
Beta	1.18
Analysts	Strong Buy
Price Target	2.00 (+227.87%)
Earnings Date	May 9, 2024

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2019
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: MNPR

Analyst Forecast

According to 2 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price forecast is $2.0, which is an increase of 227.87% from the latest price.

Price Target

$2.0

(227.87% upside)

Analyst Consensus: Strong Buy